Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
Immunocompromised patients are at risk of developing toxoplasma encephalitis (TE). Standard therapy regimens (including sulfadiazine plus pyrimethamine) are hampered by severe side effects. While atovaquone has potent in vitro activity against Toxoplasma gondii, it is poorly absorbed after oral admi...
Zapisane w:
| Wydane w: | Antimicrob Agents Chemother |
|---|---|
| Główni autorzy: | , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Society for Microbiology (ASM)
2001
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90544/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11353624/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.6.1771-1779.2001 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|